Most women in whom TFV was not detected at the first quarterly visit had none detected at subsequent visits (70% in the FTC-TDF group, 83% in the TDF group, and 72% in the TFV gel group). When participants were evaluated according to whether TFV was detected in plasma at the first quarterly visit, those in the TFV gel group with